Richard J. Benjamin Sells 9,890 Shares of Cerus Co. (CERS) Stock

Cerus Co. (NASDAQ:CERS) insider Richard J. Benjamin sold 9,890 shares of the stock in a transaction dated Wednesday, March 13th. The shares were sold at an average price of $5.96, for a total value of $58,944.40. Following the completion of the transaction, the insider now owns 3,000 shares of the company’s stock, valued at $17,880. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Shares of CERS stock traded up $0.11 on Friday, hitting $6.28. The company had a trading volume of 503,158 shares, compared to its average volume of 744,396. The stock has a market cap of $855.96 million, a price-to-earnings ratio of -14.26 and a beta of 1.44. The company has a current ratio of 2.79, a quick ratio of 2.53 and a debt-to-equity ratio of 0.26. Cerus Co. has a twelve month low of $4.70 and a twelve month high of $8.05.

Cerus (NASDAQ:CERS) last issued its quarterly earnings results on Tuesday, February 26th. The biotechnology company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.01). The company had revenue of $16.50 million during the quarter, compared to analyst estimates of $18.74 million. Cerus had a negative net margin of 84.15% and a negative return on equity of 65.35%. The company’s quarterly revenue was up 1.9% on a year-over-year basis. During the same period in the previous year, the company posted ($0.10) EPS. Sell-side analysts forecast that Cerus Co. will post -0.42 earnings per share for the current year.

CERS has been the subject of several research reports. Zacks Investment Research upgraded Cerus from a “hold” rating to a “buy” rating and set a $6.50 target price for the company in a research report on Monday, February 4th. Cantor Fitzgerald reiterated a “buy” rating and issued a $9.00 target price on shares of Cerus in a research report on Tuesday, December 18th. BidaskClub upgraded Cerus from a “hold” rating to a “buy” rating in a research report on Wednesday, February 20th. Finally, ValuEngine upgraded Cerus from a “buy” rating to a “strong-buy” rating in a research report on Monday, February 4th. Three investment analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $8.50.

Hedge funds have recently modified their holdings of the company. First Midwest Bank Trust Division increased its stake in shares of Cerus by 23.4% in the fourth quarter. First Midwest Bank Trust Division now owns 247,343 shares of the biotechnology company’s stock valued at $1,254,000 after buying an additional 46,877 shares during the period. Teachers Advisors LLC increased its stake in shares of Cerus by 3.2% in the third quarter. Teachers Advisors LLC now owns 312,076 shares of the biotechnology company’s stock valued at $2,250,000 after buying an additional 9,702 shares during the period. Peregrine Capital Management LLC increased its stake in shares of Cerus by 28.4% in the fourth quarter. Peregrine Capital Management LLC now owns 2,143,325 shares of the biotechnology company’s stock valued at $10,867,000 after buying an additional 474,106 shares during the period. Trexquant Investment LP acquired a new stake in shares of Cerus in the third quarter valued at about $255,000. Finally, BlackRock Inc. increased its stake in shares of Cerus by 2.5% in the third quarter. BlackRock Inc. now owns 10,670,764 shares of the biotechnology company’s stock valued at $76,936,000 after buying an additional 264,767 shares during the period. 65.15% of the stock is owned by institutional investors.

TRADEMARK VIOLATION NOTICE: This report was originally published by WKRB News and is the sole property of of WKRB News. If you are accessing this report on another publication, it was stolen and republished in violation of United States & international copyright & trademark laws. The original version of this report can be viewed at https://www.wkrb13.com/2019/03/15/richard-j-benjamin-sells-9890-shares-of-cerus-co-cers-stock.html.

Cerus Company Profile

Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.

Featured Story: Why is the ROA ratio important?

Insider Buying and Selling by Quarter for Cerus (NASDAQ:CERS)

Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply